Comprehensive Financial Planning Inc. PA bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 359 shares of the financial services provider’s stock, valued at approximately $47,000.
Other hedge funds have also recently bought and sold shares of the company. Huntington National Bank lifted its stake in shares of iShares Biotechnology ETF by 17.9% during the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after purchasing an additional 160 shares in the last quarter. National Bank of Canada FI increased its position in shares of iShares Biotechnology ETF by 5.9% in the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares during the last quarter. Avior Wealth Management LLC raised its stake in iShares Biotechnology ETF by 438.2% during the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after buying an additional 2,629 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares during the last quarter. Finally, Main Management ETF Advisors LLC boosted its holdings in shares of iShares Biotechnology ETF by 2.5% in the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after buying an additional 14,535 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of IBB opened at $136.15 on Tuesday. iShares Biotechnology ETF has a 12 month low of $123.60 and a 12 month high of $150.57. The stock has a fifty day moving average price of $136.10 and a 200 day moving average price of $141.27.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Insider Trading – What You Need to Know
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Market Cap Calculator: How to Calculate Market Cap
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Retail Stocks Investing, Explained
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.